241 related articles for article (PubMed ID: 30272343)
21. T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
Lamers CH; van Steenbergen-Langeveld S; van Brakel M; Groot-van Ruijven CM; van Elzakker PM; van Krimpen B; Sleijfer S; Debets R
Hum Gene Ther Methods; 2014 Dec; 25(6):345-57. PubMed ID: 25423330
[TBL] [Abstract][Full Text] [Related]
22. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation.
Duivenvoorden WC; Hopmans SN; Gallino D; Farrell T; Gerdes C; Glennie D; Lukka H; Pinthus JH
Oncol Rep; 2015 Oct; 34(4):1968-76. PubMed ID: 26252502
[TBL] [Abstract][Full Text] [Related]
24. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
[TBL] [Abstract][Full Text] [Related]
25. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
26. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
27. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Lamers CH; Willemsen RA; van Elzakker P; van Krimpen BA; Gratama JW; Debets R
Cancer Gene Ther; 2006 May; 13(5):503-9. PubMed ID: 16282986
[TBL] [Abstract][Full Text] [Related]
28. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
30. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Ziffels B; Stringhini M; Probst P; Fugmann T; Sturm T; Neri D
Mol Cancer Ther; 2019 Sep; 18(9):1544-1554. PubMed ID: 31213507
[TBL] [Abstract][Full Text] [Related]
31. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.
Haviv YS; Blackwell JL; Kanerva A; Nagi P; Krasnykh V; Dmitriev I; Wang M; Naito S; Lei X; Hemminki A; Carey D; Curiel DT
Cancer Res; 2002 Aug; 62(15):4273-81. PubMed ID: 12154029
[TBL] [Abstract][Full Text] [Related]
32. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.
Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ
Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533
[TBL] [Abstract][Full Text] [Related]
33. Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma.
Young JR; Coy H; Kim HJ; Douek M; Sisk A; Pantuck AJ; Raman SS
AJR Am J Roentgenol; 2018 Dec; 211(6):1254-1258. PubMed ID: 30300009
[TBL] [Abstract][Full Text] [Related]
34. Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ; Lee YH; Koo KC
Investig Clin Urol; 2022 Sep; 63(5):486-498. PubMed ID: 36067994
[TBL] [Abstract][Full Text] [Related]
35. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
Mukouyama H; Janzen NK; Hernandez JM; Lam JS; Caliliw R; Wang AY; Figlin RA; Belldegrun AS; Zeng G
Clin Cancer Res; 2004 Feb; 10(4):1421-9. PubMed ID: 14977845
[TBL] [Abstract][Full Text] [Related]
36. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
37. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
Lamers CH; Langeveld SC; Groot-van Ruijven CM; Debets R; Sleijfer S; Gratama JW
Cancer Immunol Immunother; 2007 Dec; 56(12):1875-83. PubMed ID: 17479266
[TBL] [Abstract][Full Text] [Related]
38. Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.
Lamers CH; van Elzakker P; van Steenbergen SC; Luider BA; Groot C; van Krimpen BA; Vulto A; Sleijfer S; Debets R; Gratama JW
Cytotherapy; 2013 May; 15(5):620-6. PubMed ID: 23388583
[TBL] [Abstract][Full Text] [Related]
39. Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Lo AS; Xu C; Murakami A; Marasco WA
Mol Ther Oncolytics; 2014; 1():14003. PubMed ID: 27119093
[TBL] [Abstract][Full Text] [Related]
40. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
